To the full analysis
Aier Eye Hospital Group stock: growth
300015.SZAier Eye Hospital Group reported $3.35B in revenue for fiscal 2025, up 6.5% on the prior year, up 13.4% a year on average over up to five years.
Daily figure as of 13 Nov 2026
Revenue (Annual rate)
28.5%
per year from 2006 to 2025, per share 23.2%
Earnings (Annual rate)
32.9%
per year from 2006 to 2025, per share 27.4%
Free cash flow (Annual rate)
no data
Growth per year by period
What reaches shareholders is growth per share: buybacks lift it, new shares dilute it.
| since 2020 | since 2015 | since 2006 | |
|---|---|---|---|
| Revenue | 13.4% | 21.6% | 28.5% |
| Revenue per share | 12.6% | 20.2% | 23.2% |
| Earnings | 13.5% | 22.4% | 32.9% |
| Earnings per share | 13.0% | 20.8% | 27.4% |
| Free cash flow | 9.6% | 31.0% | no data |
| Free cash flow per share | 8.8% | 29.5% | no data |
Fiscal years at a glance
How revenue and earnings grow
- Revenue
- Earnings
- Free cash flow
Figures as a table
| Year | Revenue | Earnings | Free cash flow |
|---|---|---|---|
| 2006 | $28.67M | $2.19M | −$11.45M |
| 2007 | $47.22M | $5.85M | −$562.42K |
| 2008 | $63.77M | $9.2M | $4.56M |
| 2009 | $89.88M | $13.87M | $3.23M |
| 2010 | $129.7M | $18.04M | −$950.31K |
| 2011 | $196.55M | $25.78M | −$546.83K |
| 2012 | $245.96M | $27.38M | $11.35M |
| 2013 | $297.67M | $33.52M | $32.68M |
| 2014 | $360.22M | $46.37M | $41.54M |
| 2015 | $474.72M | $64.19M | $39.2M |
| 2016 | $599.92M | $83.53M | $54.06M |
| 2017 | $894.21M | $111.35M | $108.7M |
| 2018 | $1.2B | $151.3M | $88.36M |
| 2019 | $1.5B | $206.79M | $199.87M |
| 2020 | $1.79B | $258.51M | $367.4M |
| 2021 | $2.25B | $348.42M | $388.41M |
| 2022 | $2.42B | $378.54M | $465.25M |
| 2023 | $3.05B | $503.71M | $661.67M |
| 2024 | $3.15B | $533.28M | $457.63M |
| 2025 | $3.35B | $485.92M | $581.87M |
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Currency
- Amounts in US dollars, converted at the ECB reference rate of 12 Nov 2026 ($1 = CN¥6.6683)
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Neutral, published since 7 Nov 2026 (in the score history since 14 Aug 2026)
- Valuation signal Undervalued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.